Back to results
US 2021/0079082 A1Published application
C-terminal antibody variants
AssigneeAmgen Inc.
InventorsZhe Huang, Jennitte LeAnn Stevens, Greg Flynn, Szilan Fodor, Mark Daris
Life of this patent
Estimating the term…
Abstract
The invention generally relates to anti-sclerostin antibodies having C-terminal modifications, and compositions comprising such antibodies.
Claims25
An antibody that specifically binds to sclerostin of SEQ ID NO:
- 1 and comprises a set of six CDRs set forth in SEQ ID NOs:
- 2-7, wherein the antibody comprises a heavy chain comprising the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO:
- 8) at the C-terminus of the heavy chain.
Dependencies are inferred from the claim text.